Serafin Morales Murillo

Jimenez, MM; Zielinski, C; Ruiz-Borrego, M; Carrasco, E; Ciruelos, EM; Munoz, M; Bermejo, B; Margeli, M; Csoszi, T; Anton, A; Turner, N; Casas, MI; Morales, S; Alba, E; Calvo, L; De la Haba, J; Ramos, M; Corsaro, M; Kahan, Z; Gil-Gil, M

Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormonereceptor+/HER2-metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study

ANNALS OF ONCOLOGY 32 457-458. 01/01/2021.

[doi:10.1016/j.annonc.2021.08.512]

Ciruelos E; Villagrasa P; Pascual T; Oliveira M; Pernas S; Paré L; Escrivá-de-Romaní S; Manso L; Adamo B; Martínez E; Cortés J; Vazquez S; Perelló A; Garau I; Melé M; Martínez N; Montaño A; Bermejo B; Morales S; Echarri MJ; Vega E; González-Farré B; Martínez D; Galván P; Canes J; Nuciforo P; Gonzalez X; Prat A

Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial.

CLINICAL CANCER RESEARCH 26 5820-5829. 15/11/2020.

[doi:10.1158/1078-0432.CCR-20-0844]

Quintela-Fandino M; Holgado E; Manso L; Morales S; Bermejo B; Colomer R; Apala JV; Blanco R; Muñoz M; Caleiras E; Iranzo V; Martinez M; Dominguez O; Hornedo J; Gonzalez-Cortijo L; Cortes J; Gasol Cudos A; Malon D; Lopez-Alonso A; Moreno-Ortíz MC; Mouron S; Mañes S

Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial.

BREAST CANCER RESEARCH 22 124-124. 11/11/2020.

[doi:10.1186/s13058-020-01362-y]

Morales, S; Cudos, AG; Galindo, AR; Velasco, A; Morales, CC; Guzman, DRS; Olive, JM

Loss of HER2 after neoadjuvant treatment of HER2+early breast cancer

ANNALS OF ONCOLOGY 31 51-51. 01/05/2020.

[doi:10.1016/j.annonc.2020.03.042]

Griguolo, G; Serna, G; Pascual, T; Fasani, R; Chic, N; Pare, L; Pernas, S; Munoz, M; Oliveira, M; Vidal, M; Cussac, AL; Cortes, J; Galvan, P; Bermejo, B; Martinez, N; Lopez, R; Morales, S; Villagrasa, P; Prat, A; Nuciforo, P

Characterization of immune microenvironment before and following anti-HER2 neoadjuvant therapy (NAT)

ANNALS OF ONCOLOGY 31 19-19. 01/05/2020.

[doi:10.1016/j.annonc.2020.03.144]

Martin, M; Zielinski, C; Ruiz-Borrego, M; Carrasco, E; Ciruelos, E; Munoz, M; Bermejo, B; Margeli, M; Turner, N; Casas, M; Anton, A; Csoszi, T; Corsaro, M; Murillo, L; Morales, S; Alba, E; Bartlett, CH; Koehler, M; Guerrero, A; Kahan, Z; Gil-Gil, M

Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006): A phase 3 trial of Palbociclib (PAL) in combination with endocrine therapy (ET) versus Capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (MBC) patients (pts) whose disease progressed on aromatase inhibitors (AIs)

CANCER RESEARCH 80 -. 01/02/2020.

[doi:10.1158/1538-7445.SABCS19-GS2-07]

Braso-Maristany, F; Griguolo, G; Pascual, T; Pare, L; Nuciforo, P; Llombart-Cussac, A; Bermejo, B; Oliveira, M; Morales, S; Martinez, N; Vidal, M; Adamo, B; Martinez, O; Pernas, S; Lopez, R; Muñoz M; Chic, N; Galvan, P; Garau, I; Manso, L; Alarcon, J; Martinez, E; Gregorio, S; Gomis, RR; Villagrasa, P; Cortes, J; Ciruelos, E; Prat, A

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade.

Nature Communications 11 385-385. 20/01/2020.

[doi:10.1038/s41467-019-14111-3]

Manso L; Hernando C; Galán M; Oliveira M; Cabrera MA; Bratos R; Rodríguez CA; Ruiz-Borrego M; Blanch S; Llombart-Cussac A; Delgado-Mingorance JI; Álvarez-Busto I; Gallegos I; González-Cortijo L; Morales S; Aguirre E; Hernando BA; Ballesteros A; Alés-Martínez JE; Reboredo C; Oltra A; González-Cao M; Santisteban M; Malón D; Echeverría I; García-Garre E; Vega E; Servitja S; Andrés R; Robles CE; López R; Galve E; Echarri MJ; Legeren M; Moreno F

Palbociclib combined with endocrine therapy in heavily pretreated HR(+)/HER2(-) advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP).

BREAST 54 286-292. 01/01/2020.

[doi:10.1016/j.breast.2020.11.005]

Quintela-Fandino, M; Morales, S; Cortes-Salgado, A; Manso, L; Apala, JV; Munoz, M; Cudos, AG; Fortuny, JS; Gion, M; Lopez-Alonso, A; Cortes, J; Guerra, J; Malon, D; Caleiras, E; Mulero, F; Mouron, S

Randomized Phase O/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer

CLINICAL CANCER RESEARCH 26 35-45. 01/01/2020.

[doi:10.1158/1078-0432.CCR-19-2023]

Prat, A; Pascual, T; De Angelis, C; Gutierrez, C; Llombart-Cussac, A; Wang, T; Cortes, J; Rexer, B; Pare, L; Forero, A; Wolff, AC; Morales, S; Adamo, B; Braso-Maristany, F; Vidal, M; Veeraraghavan, J; Krop, I; Galvan, P; Pavlick, AC; Bermejo, B; Izquierdo, M; Rodrik-Outmezguine, V; Reis-Filho, JS; Hilsenbeck, SG; Oliveira, M; Dieci, MV; Griguolo, G; Fasani, R; Nuciforo, P; Parker, JS; Conte, P; Schiff, R; Guarneri, V; Osborne, CK; Rimawi, MF

HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE 112 46-54. 01/01/2020.

[doi:10.1093/jnci/djz042]

MORALES MURILLO, SERAFIN

Clinical Benefit with Palbociclib in Estrogen Receptor-Positive, Her2-Negative Metastatic Breast Cancer: New Concepts

Clinics of Oncology 2 -. 20/11/2019.

Ciruelos, EM; Diaz, MN; Isla, MD; Lopez, R; Bernabe, R; Gonzalez, E; Cirauqui, B; Coves, J; Morales, S; Arcediano, A; Barneto, I; Cerezuela, P; Illarramendi, JJ; Morales, C; Ponce, S

Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer

EUROPEAN JOURNAL OF CANCER CARE 28 -. 01/11/2019.

[doi:10.1111/ecc.13164]